{
    "clinical_study": {
        "@rank": "31993", 
        "brief_summary": {
            "textblock": "To evaluate the clinical toxicity, safety, and MTD of WF 10 ( TCDO ) intravenous solution\n      administered to patients with HIV infection. To evaluate the potential anti-HIV activity of\n      TCDO."
        }, 
        "brief_title": "A Phase I/II Clinical Study of WF 10 IV Solution ( TCDO ) in Patients With HIV Infection", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Concurrent Medication:\n\n        Required:\n\n          -  Aerosolized pentamidine (300 mg monthly) as prophylaxis for PCP only in patients with\n             CD4 count <= 200 cells/mm3.\n\n        Allowed:\n\n          -  PCP prophylaxis with aerosolized pentamidine in patients with CD4 count > 200\n             cells/mm3, only at the discretion of the treating physician.\n\n        Patients must have:\n\n          -  HIV positivity.\n\n          -  Absolute CD4 count of 150 - 500 cells/mm3.\n\n          -  At least 6 months of prior zidovudine therapy.\n\n          -  No active opportunistic infection requiring ongoing therapy.\n\n          -  Life expectancy of at least 6 months.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following symptoms or conditions are excluded:\n\n          -  Neoplasm other than basal cell carcinoma of the skin.\n\n          -  Clinically significant cardiac disease.\n\n          -  Abnormal neurological status by a standardized assessment including strength, reflex\n             testing, and sensory testing.\n\n          -  Unwilling to comply with protocol requirements.\n\n        Patients with the following prior conditions are excluded:\n\n        History of myocardial infarction or arrhythmias.\n\n        Prior Medication:\n\n        Excluded within 2 weeks prior to study entry:\n\n          -  Antiretroviral agent or interferon.\n\n          -  Systemic biologic response modifiers, corticosteroids, cytotoxic chemotherapeutic\n             agents, or other drugs that can cause neutropenia or significant nephrotoxicity.\n\n          -  Rifampin or rifampin derivatives.\n\n          -  Systemic anti-infectives.\n\n        Required:\n\n          -  At least 6 months of prior zidovudine. Active drug or alcohol abuse."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002119", 
            "org_study_id": "222A", 
            "secondary_id": "WF10-92-US-001"
        }, 
        "intervention": {
            "intervention_name": "WF10", 
            "intervention_type": "Drug"
        }, 
        "keyword": [
            "Acquired Immunodeficiency Syndrome", 
            "AIDS-Related Complex", 
            "Antiviral Agents"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "Houston", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "77074"
                }, 
                "name": "Oncol Med Associates"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Phase I/II Clinical Study of WF 10 IV Solution ( TCDO ) in Patients With HIV Infection", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "reference": [
            {
                "citation": "Busch HW, Christensen S, Reichelt D, Jahn S, Zidek W. Treatment of HIV-infected patients with advanced symptomatic disease with WF10 solution (TCDO). Int Conf AIDS. 1994 Aug 7-12;10(1):204 (abstract no PB0245)"
            }, 
            {
                "citation": "Kahn JO, McGrath MS, Ching OM, Kuhne FW. A single center, phase 2 study evaluating the effects of WF10. Int Conf AIDS. 1998;12:349 (abstract no 22423)"
            }, 
            {
                "PMID": "9717676", 
                "citation": "Raffanti SP, Schaffner W, Federspiel CF, Blackwell RB, Ching OA, K\u00fchne FW. Randomized, double-blind, placebo-controlled trial of the immune modulator WF10 in patients with advanced AIDS. Infection. 1998 Jul-Aug;26(4):202-7."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002119"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Oxo Chemie GmbH", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Safety Study, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 1996"
    }, 
    "geocoordinates": {
        "Oncol Med Associates": "29.76 -95.369"
    }
}